R&D investments are paramount to our mission, and we are committed to intensifying our efforts in the region
In Conversation
COFEPRIS decided to introduce ten regulations for health purposes, and three of these were specifically for medical devices. This prioritization underscores the importance of our contributions…
Our portfolio is deliberately diversified to mitigate reliance on any single segment
The regulatory environment in China, guided by the NMPA, appears to be evolving positively, providing a conducive framework for pharmaceutical innovation and growth
In Saudi Arabia, there is a keen interest in being at the forefront of adopting pioneering technologies and conducting research to validate their efficacy.
We are working towards creating a private sector ecosystem that can cater to broader healthcare transformation
We can't afford to have companies withdraw from infectious disease research—it's crucial for global health security
We recognize the value of the existing infrastructure and services provided by both the new GBACTI and the existing HKU-CTC. By working together, we can ensure…
We like to call ourselves ‘innovation hunters’ because we're not just after any innovation, but rather those that address unmet medical needs and have a tangible…
Success in business requires more than just aggression—it requires strategy, understanding, and relentless dedication
We're about to inaugurate a new manufacturing unit for Halewood, which will be a state-of-the-art facility with international certifications like US FDA approval
We've strived for a culture rooted in fairness, transparency, and hard work
